R1

Personalised Cancer Vaccines Clear Phase III
Intismeran autogene plus pembrolizumab reduced melanoma recurrence or death by 42% in the first positive Phase III trial of an individualised mRNA neoantigen therapy. The science has crossed an important threshold. Manufacturing, reimbursement and equitable delivery now become part of the clinical question.

FDA Puts Alzheimer’s Prevention on the Trial Agenda

Energy drinks went mainstream before their cardiac safety evidence did

A Self-Guided Pathway for Functional Seizures

Ebola’s Vaccine Trial Enters New Territory

Brown fat is looking less like a metabolic curiosity and more like a drug target

A Second Step for Alzheimer’s Blood Tests

A Genetic Clue to Spinal Leukodystrophy

Endometrial Cancer Gets a Strong ADC Win

A filter can blunt pollution’s cardiac effects. It cannot be the policy
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
